Management of childhood aplastic anemia following liver transplantation for nonviral hepatitis: A French survey.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
04 2020
Historique:
received: 13 08 2019
revised: 18 12 2019
accepted: 21 12 2019
pubmed: 12 1 2020
medline: 1 7 2020
entrez: 12 1 2020
Statut: ppublish

Résumé

Hepatitis-associated aplastic anemia (AA) is a rare syndrome combining acute hepatitis of variable severity and AA. Hepatitis may be severe enough to require urgent liver transplantation (LT). Herein, we describe clinical presentation and management of a cohort of pediatric patients diagnosed with AA after undergoing LT for nonviral hepatitis. To describe this rare clinical situation, we performed a national survey and identified nine children treated for AA following LT during the last 10 years in France. All patients were treated first for hepatic failure with urgent LT. AA was diagnosed with a median delay of 34 days [21-200] from the diagnosis of hepatitis. Seven children were treated with antithymocyte globulin/cyclosporine, one with CSA alone and one received bone marrow transplantation. At the last visit (median follow-up: 4 years), outcomes were excellent: all patients were alive and in hematological remission (complete remission: 7; partial remission: 2). Immunosuppressive therapy was pursued in all patients due to the liver transplant. No unusual toxicities were reported. AA after LT is considered a therapeutic challenge. Nevertheless, hematological outcome is good using a standard immunosuppressive approach.

Sections du résumé

BACKGROUND
Hepatitis-associated aplastic anemia (AA) is a rare syndrome combining acute hepatitis of variable severity and AA. Hepatitis may be severe enough to require urgent liver transplantation (LT). Herein, we describe clinical presentation and management of a cohort of pediatric patients diagnosed with AA after undergoing LT for nonviral hepatitis.
METHODS
To describe this rare clinical situation, we performed a national survey and identified nine children treated for AA following LT during the last 10 years in France.
RESULTS
All patients were treated first for hepatic failure with urgent LT. AA was diagnosed with a median delay of 34 days [21-200] from the diagnosis of hepatitis. Seven children were treated with antithymocyte globulin/cyclosporine, one with CSA alone and one received bone marrow transplantation. At the last visit (median follow-up: 4 years), outcomes were excellent: all patients were alive and in hematological remission (complete remission: 7; partial remission: 2). Immunosuppressive therapy was pursued in all patients due to the liver transplant. No unusual toxicities were reported.
CONCLUSION
AA after LT is considered a therapeutic challenge. Nevertheless, hematological outcome is good using a standard immunosuppressive approach.

Identifiants

pubmed: 31925926
doi: 10.1002/pbc.28177
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28177

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

Camitta BM, Storb R, Thomas ED. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306(11):645-652.
Camitta BM, Storb R, Thomas ED. Aplastic anemia (second of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306(12):712-718.
Iwafuchi H. The histopathology of bone marrow failure in children. J Clin Exp Hematop. 2018;58(2):68-86.
Gonzalez-Casas R, Garcia-Buey L, Jones EA, Gisbert JP, Moreno-Otero R. Systematic review: hepatitis-associated aplastic anaemia-a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther. 2009;30(5):436-443.
Tzakis AG, Arditi M, Whitington PF, et al. Aplastic anemia complicating orthotopic liver transplantation for non-A, non-B hepatitis. N Engl J Med. 1988;319(7):393-396.
Rauff B, Idrees M, Shah SAR, et al. Hepatitis associated aplastic anemia: a review. Virol J. 2011;8:87.
Patel KR, Bertuch A, Sasa GS, Himes RW, Wu H. Features of hepatitis in hepatitis-associated aplastic anemia: clinical and histopathologic study. J Pediatr Gastroenterol Nutr. 2017;64(1):e7-e12.
Mali VP, Tan PL, Aw M, et al. Mismatched bone marrow transplantation for severe aplastic anaemia after liver transplantation for associated acute liver failure. Ann Acad Med Singap. 2011;40(9):420-421.
Stock PG, Steiner ME, Freese D, Sharp H, Ascher NL. Hepatitis-associated aplastic anemia after liver transplantation. Transplantation. 1987;43(4):595-597.
Kawahara K, Storb R, Sanders J, Petersen FB. Successful allogeneic bone marrow transplantation in a 6.5-year-old male for severe aplastic anemia complicating orthotopic liver transplantation for fulminant non-A-non-B hepatitis. Blood. 1991;78(4):1140-1143.
European Group for Blood and Marrow Transplantation. The Complete Treatment Algorithm for SAA. https://portal.ebmt.org/Contents/Resources/Library/Slidebank/EBMT2010SlideBank/Documents/EBMT%202010%20Session%20slides/SAA_complete_treat_algorithm_v1.pdf. Accessed March 17, 2019.
Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207.
Maggiore G, Socie G, Sciveres M, et al. Seronegative autoimmune hepatitis in children: spectrum of disorders. Dig Liver Dis. 2016;48(7):785-791.
Lu J, Basu A, Melenhorst JJ, Young NS, Brown KE. Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood. 2004;103(12):4588-4593.
De Bruyne RML, Dhawan A. Bone marrow dysfunction following pediatric liver transplantation. Pediatr Transplant. 2005;9(4):423-426.
Aydoğdu S, Tümgör G, Karapinar DY, et al. Severe aplastic anemia following liver transplantation in a patient with non-A-E fulminant hepatitis. Turk J Gastroenterol. 2011;22(3):337-340.
Rawal N, Yazigi N. Pediatric liver transplantation. Pediatr Clin North Am. 2017;64(3):677-684.
Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2014;59(1):112-131.
Park HS, Park SN, Im K, et al. Telomere length and somatic mutations in correlation with response to immunosuppressive treatment in aplastic anaemia. Br J Haematol. 2017;178(4):603-615.
Locasciulli A, Bacigalupo A, Bruno B, et al. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party: hepatitis-associated aplasia: epidemiology and outcome. Br J Haematol. 2010;149(6):890-895.
Alashkar F, Föhring D, Dührsen U, Baba HA, Röth A. Cytopenia first - hepatitis second: an unusual sequence in aplastic anemia. Clin Case Rep. 2017;5(6):778-781.
Wang H, Tu M, Fu R, et al. The clinical and immune characteristics of patients with hepatitis-associated aplastic anemia in China. PLoS One. 2014;9(5):e98142.
Fuhrer M. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106(6):2102-2104.
Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430-438.
Ikawa Y, Nishimura R, Kuroda R, et al. Expansion of a liver-infiltrating cytotoxic T-lymphocyte clone in concert with the development of hepatitis-associated aplastic anaemia. Br J Haematol. 2013;161(4):599-602.
Babushok DV, Grignon A-L, Li Y, et al. Disrupted lymphocyte homeostasis in hepatitis-associated acquired aplastic anemia is associated with short telomeres: short telomeres in hepatitis-associated aplastic anemia. Am J Hematol. 2016;91(2):243-247.
Rogers ZR, Nakano TA, Olson TS, et al. Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica. 2019;104(10):1974-1983.
Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party. Br J Haematol. 2015;171(4):585-594.
Dufour C, Pillon M, Sociè G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565-573.
McCormack PL. Eltrombopag: a review of its use in patients with severe aplastic anaemia. Drugs. 2015;75(5):525-531.

Auteurs

Fanny Delehaye (F)

Department of Pediatric Hematology and Oncology, University Hospital of Caen, Caen, France.

Dalila Habes (D)

Department of Pediatric Hepatology, AP-HP, Kremlin-Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Marie-Emilie Dourthe (ME)

Department of Pediatric Hematology and Immunology, AP-HP, Robert-Debré Hospital, Paris, France.

Yves Bertrand (Y)

Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France.

Gerard Michel (G)

Department of Pediatric Hematology and Oncology and Research Unit EA 3279, Timone Enfants Hospital and Aix-Marseille University, Marseille, France.

Jérémie Gaudichon (J)

Department of Pediatric Hematology and Oncology, University Hospital of Caen, Caen, France.

Dominique Debray (D)

Unit of Pediatric Hepatology, Reference Center for Rare Pediatric Liver Diseases, Necker-Enfants-Malades University Hospital, Paris, France.
Department of medicine, University of Paris-Descartes, Sorbonne Paris-Cité, Paris, France.

Brigitte Nelken (B)

Department of Pediatric Hematology-Oncology, Jeanne de Flandre Hospital, CHRU, Lille, France.

Marlène Pasquet (M)

Department of Pediatric Hematology and Oncology, University hospital of Toulouse, Toulouse, France.

Stéphane Blanche (S)

Department of Pediatric Hematology, Immunology and Rheumatology, AP-HP, Necker Enfants-Malades Hospital, Paris, France.

Thierry Leblanc (T)

Department of Pediatric Hematology and Immunology, AP-HP, Robert-Debré Hospital, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH